Did you mean aromatase inhibitor?
Displaying drugs 576 - 600 of 2444 in total
Luliconazole
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (weak) …
Amiodarone
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone...
Approved
Investigational
Matched Categories: … OCT2 Inhibitors ... BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Ataluren
Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose...
Approved
Investigational
Matched Categories: … OATP1B3 inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …
Quinupristin
Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more...
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Entacapone
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of...
Approved
Investigational
Matched Categories: … COMT Inhibitors ... Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (weak) …
Hydroxyurea
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea...
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Nalidixic acid
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Dosulepin
Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. Dosulepin inhibits...
Approved
Matched Categories: … Adrenergic Uptake Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Enoxacin
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Moxifloxacin
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Lomustine
An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (weak) …
Nicardipine
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Fluoxetine
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Approved
Vet approved
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Edetate disodium anhydrous
Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Folic acid
Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA...
Approved
Nutraceutical
Vet approved
Matched Description: … and amino acids, is disrupted by anti-metabolite therapies such as [DB00563] as they function as DHFR inhibitors …
Matched Categories: … OAT1/SLC22A6 inhibitors …
Matched Categories: … OAT1/SLC22A6 inhibitors …
Noscapine
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Midostaurin
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Istradefylline
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A2A receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline...
Approved
Investigational
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... OATP1B3 inhibitors …
Cerivastatin
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Alatrofloxacin
Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors …
Orphenadrine
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Ivacaftor
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012 , and by Health Canada in late 2012. Ivacaftor is administered...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …
Antithrombin Alfa
Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Approved
Investigational
Matched Categories: … Factor Xa Inhibitors ... Thrombin Inhibitors …
Teniposide
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic...
Approved
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Nitisinone
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Hydroxyphenylpyruvate Dioxygenase Inhibitors ... 4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors …
Displaying drugs 576 - 600 of 2444 in total